AstraZeneca Announces Share Capital and Voting Rights Update

An update from AstraZeneca ( (GB:AZN) ) is now available.

AstraZeneca has announced that as of 31 May 2025, its issued share capital with voting rights consists of 1,550,657,962 ordinary shares. This figure is significant for shareholders as it serves as the denominator for calculating their interests under the UK Financial Conduct Authority’s Disclosure and Transparency Rules.

The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Spark’s Take on GB:AZN Stock

According to Spark, TipRanks’ AI Analyst, GB:AZN is a Outperform.

AstraZeneca’s overall score is driven by strong financial performance and positive corporate developments. While technical indicators and valuation present moderate concerns, the company’s strategic advancements and robust earnings outlook provide a solid investment case.

To see Spark’s full report on GB:AZN stock, click here.

More about AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company based in Cambridge, UK. It focuses on the discovery, development, and commercialization of prescription medicines in areas such as Oncology, Rare Diseases, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its innovative medicines are sold in over 125 countries and used by millions of patients worldwide.

Average Trading Volume: 2,627,131

Technical Sentiment Signal: Hold

Current Market Cap: £166.2B

See more data about AZN stock on TipRanks’ Stock Analysis page.